Related Experiment Video
Updated: Jun 13, 2026
Immunofluorescent Labeling in Nasal Mucosa Tissue Sections of Allergic Rhinitis Rats via Multicolor Immunoassay
Published on: September 22, 2023
Is there a role for leukotriene antagonists in the prevention of recurrent nasal polyps?
1Department of Otorhinolaryngology, Paracelsus Medical University, A-5020 Salzburg, Austria. g.rasp@salk.at
Purpose Of Review:
The aim of this review is to provide the current available data for leukotriene receptor antagonists in the treatment of nasal polyps, the use in the postoperative therapy single or as an add-on to standard treatments.
Recent Findings:
Surgical treatment of nasal polyps was refined in the last 30 years by the introduction of functional endoscopic sinus surgery and nasal endoscopy for monitoring nasal polyp patients. As the relapse is the main challenge and as nasal steroids only delay it, a more efficient treatment is needed. Leukotriene antagonists have effects on asthma and allergic rhinitis; preliminary data show some benefits in nasal polyps.
Summary:
In the surgery of nasal polyps, recurrence is the main problem. Steroids are the current standard therapy, but the limitations are obvious. The role of leukotrienes in the disorder of nasal polyps is well established now, and with the antagonists available, interest rose in treating nasal polyps. A total of 356 patients took part in several studies involving leukotriene antagonists in the nasal polyp population. Some studies have minor levels of evidence; the data show positive effects for patients in preoperative and postoperative studies and medical treatments. There were benefits as an add-on to steroids and data from allergic rhinitis studies also show possible synergism with antihistamines. There are hints for a positive effect on eosinophil inflammation, clinical symptom scores, nasal airflow, sneezing and postnasal drip. Although some effects are shown, more controlled studies are necessary for reliable data.
Insights
Leukotriene receptor antagonists show promise in treating nasal polyps, potentially improving symptoms and reducing recurrence after surgery. Further research is needed to confirm their efficacy as a standalone or add-on therapy.
Area of Science:
- Otolaryngology
- Allergy and Immunology
- Pharmacology
Background:
- Nasal polyps significantly impact quality of life, with recurrence being a major challenge post-surgery.
- Current standard treatments, including nasal steroids, have limitations in preventing polyp regrowth.
- Leukotriene pathways are implicated in nasal polyp development, suggesting a therapeutic target.
Purpose of the Study:
- To review current data on leukotriene receptor antagonists (LTRAs) for nasal polyp treatment.
- To evaluate LTRAs as a single or add-on therapy in preoperative and postoperative settings.
- To assess the role of LTRAs in managing eosinophilic inflammation and associated symptoms.
Main Methods:
- Systematic review of studies involving LTRAs in patients with nasal polyps.
- Analysis of data from 356 patients across various treatment protocols.
- Inclusion of studies examining LTRAs as monotherapy, add-on to steroids, and in conjunction with antihistamines.
Main Results:
- Preliminary data suggest LTRAs offer benefits in nasal polyp treatment, with positive effects noted in preoperative and postoperative patient groups.
- Evidence indicates potential benefits when used as an add-on to corticosteroid therapy.
- Observed improvements in eosinophil inflammation, clinical symptom scores, nasal airflow, sneezing, and postnasal drip.
Conclusions:
- Leukotriene receptor antagonists demonstrate potential in managing nasal polyps, addressing limitations of current therapies.
- LTRAs may offer synergistic effects with antihistamines and improve key clinical outcomes.
- While promising, more high-quality, controlled studies are required to establish definitive efficacy and optimal use of LTRAs in nasal polyp management.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:16Drugs Used in Upper Respiratory Disorders: Overview
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
01:23Chronic Pharyngitis
Etiology
It often arises from persistent viral or bacterial infections affecting sinuses and tonsils.
Additional contributing factors include inadequate dental hygiene, mouth breathing, recurring tonsillitis, allergic rhinitis, laryngopharyngeal reflux, and exposure to smoke, chemicals, and other environmental pollutants. Allergic reactions to pollen, mold, and pet dander, chronic cough, excessive voice usage,...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...